> INVESTORS   Overview   Corporate Structure   Corporate Governance   Company History   Annual General Meeting   Postal Ballot   Investor FAQs   Stock Info   Financial Results   Subsidiary Financials   Annual Report   Disclosure to Stock Exchange   Nomination form   Press Releases   Presentations   Analyst Coverage   Investor Contacts

Disclosure to Stock Exchange   December 2019 26 Dec Intimation for Incorporation of Biocon Biosphere Limited as Wholly Owned Subsidiary of the Company 13 Dec Updated Investor Presentation on "Biocon Biologics - Transforming Healthcare. Transforming Lives" 12 Dec Change in name of Company's Registrar and Share Transfer Agent 12 Dec Meeting conducted with Institutional Investors / Analysts 12 Dec Press Release 11 Dec Investor Presentation on "Biocon Biologics - Transforming Healthcare. Transforming Lives" 11 Dec Meetings conducted with Institutional Investors / Analysts 10 Dec Meetings conducted with Institutional Investors / Analysts 06 Dec Meetings conducted with Institutional Investors / Analysts 05 Dec Meetings conducted with Institutional Investors / Analysts 04 Dec Meetings conducted with Institutional Investors / Analysts 03 Dec Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally 03 Dec Siddharth Mittal Takes Over as CEO and Joint Managing Director of Biocon Limited 02 Dec Biocon and Mylan Launch Trastuzumab Biosimilar, OgivriTM (trastuzumab-dkst), in the U.S.   November 2019 28 Nov Meetings conducted with Institutional Investors / Analysts. 27 Nov USFDA Approves Biocon’s sBLA for Pegfilgrastim New Manufacturing Facility 22 Nov Disclosure of Related Party Transactions for the half year ended September 30, 2019 21 Nov Meetings conducted with Institutional Investors / Analysts. 18 Nov Press Release 12 Nov Press Release 12 Nov Meetings conducted with Institutional Investors / Analyst 05 Nov Meetings conducted with Institutional Investors / Analyst 05 Nov Press Release   October 2019 31 Oct Meeting conducted with Institutional Investors / Analysts 28 Oct Press Release 23 Oct Outcome of Board Meeting 23 Oct Press Release on Q2 FY20 Financial Results 23 Oct Change in Directorate and Key Managerial Personnel 10 Oct Notice of Board Meeting – Newspaper Advertisement 10 Oct Press Release 03 Oct Intimation of Board Meeting and Trading Window Closure 03 Oct Press Release 01 Oct Meeting conducted with Institutional Investors / Analysts   September 2019 27 Sep Meeting conducted with Institutional Investors / Analysts 24 Sep Meeting conducted with Institutional Investors / Analysts 24 Sep Public Announcement 20 Sep U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru 19 Sep Meeting conducted with Institutional Investors / Analysts 12 Sep Press Release 12 Sep Meetings conducted with Institutional Investors / Analyst 11 Sep Revised Investor Presentation for Quarter ended June 30, 2019 11 Sep Meetings conducted with Institutional Investors / Analyst 10 Sep Meetings conducted with Institutional Investors / Analyst 09 Sep Investor Presentation for Quarter ended June 30, 2019. 06 Sep Meetings conducted with Institutional Investors / Analysts. 04 Sep Meetings conducted with Institutional Investors / Analysts.   August 2019 31 Aug Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015 29 Aug Meeting conducted with Institutional Investors/ Analysts. 27 Aug Meetings conducted with Institutional Investors/ Analysts. 21 Aug Meetings conducted with Institutional Investors/Analysts 3 Aug Meeting conducted with Institutional Investors/ Analysts. 1 Aug Press Release titled Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia   July 2019 31 July Change in Directorate 31 July Meeting conducted with Institutional Investors/Research Analysts 30 July Meeting conducted with Institutional Investors/Research Analysts 27 July Voting Results along with Scrutinizer’s report and Proceeding of 41st AGM 25 July Press Release on Q1 FY20 financial results 25 July Outcome of Board Meeting - Financial Results for the quarter ended June 30, 2019 25 July Appointment of Mr. Mayank Verma as Company Secretary and Compliance Officer 08 July Pre -Approval U.S. FDA Inspection Conducted at Biocon's lnsulins Facilities in Malaysia 05 July Newspaper advertisement confirming dispatch of Notice of the 41st AGM and the Annual Report for the FY 2018-19. 05 July Notice of Board Meeting – Newspaper Advertisement 05 July Dividend Updates 04 July Intimation of Board Meeting and Trading Window Closure   June 2019 28 June Meetings conducted with Institutional Investors/Research Analysts. 28 June Notice of 41st Annual General Meeting and the Annual Report for the FY 2018-19 of the Company. 27 June Meetings conducted with Institutional Investors/Research Analysts. 19 June Newspaper Advertisement for transfer of equity shares to IEPF 19 June Meetings conducted with Institutional Investors/Research Analysts 17 June Outcome of the Board meeting 17 June Meetings conducted with Institutional Investors/Research Analysts. 15 June Allotment of Bonus Equity Shares 14 June Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification 14 June Meetings conducted with Institutional Investors/Research Analysts. 13 June Investor Presentation on "Biosimilars- The Next Big Global Healthcare Opportunity 12 June Meetings conducted with Institutional Investors/Research Analysts. 07 June Meetings conducted with Institutional Investors/Research Analysts. 04 June Postal Ballot – Voting Result along with Scrutinizers Report and amended Memorandum of Association 04 June Meetings conducted with Institutional Investors/Research Analysts.   May 2019 31 May Intimation of Record Date for Issue of Bonus Shares 30 May Meetings conducted with Institutional Investors/Research Analysts. 29 May Meeting conducted with Institutional Investors/Research Analysts. 27 May Investor Presentation for Quarter ended March 31, 2019. 24 May Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("SEBI Listing Regulation") 22 May Press Release - Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. 16 May Press Release - Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. 16 May Meeting conducted with Institutional Investors/Research Analysts. 10 May Meeting conducted with Institutional Investors/Research Analysts. 09 May Meeting conducted with Institutional Investors/Research Analysts. 07 May Newspaper Advertisement for Notice of Postal Ballot 07 May Meeting conducted with Institutional Investors/Research Analysts. 03 May Postal Ballot Notice under Regulation 30 of SEBI (listing Obligation and Disclosure Requirements), Regulations, 2015 ("SEBI Listing Regulations") 03 May Meetings conducted with Institutional Investors/Research Analysts.   April 2019 30 Apr Meetings conducted with Institutional Investors/Research Analysts. 25 Apr Outcome of the Board Meeting 22 Apr Intimation for proposal to consider and recommendation of Final Dividend and Bonus issue by the Company 11 Apr Intimation of Board Meeting 02 Apr  Outcome of Board meeting held on April 1,  2019   March 2019 29 Mar Meetings conducted with Institutional Investors/Research Analysts. 16 Mar Intimation for change in Compliance Officer 15 Mar Meetings conducted with Institutional Investors/Research Analysts 13 Mar Outcome of Meeting - Postal Ballot 13 Mar Result Announcement Postal Ballot 11 Mar Meeting conducted with Institutional Investors/Research Analysts. 07 Mar Meetings conducted with Institutional Investors/Research Analysts. 06 Mar Meetings conducted with Institutional Investors/Research Analysts. 06 Mar Biocon Facility Completes Pre Approval U.S. FDA Inspection 05 Mar Meetings conducted with Institutional Investors/Research Analysts. 02 Mar Biocon Appoints Dr. Christiane Hamacher as CEO of Biocon Biologics India Limited. 01 Mar Meeting conducted with Institutional Investors/Research Analysts   February 2019 26 Feb Meetings conducted with Institutional Investors/Research Analysts. 18 Feb Biocon Facilities complete Pre Approval U.S.FDA lnspection 15 Feb Meetings conducted with Institutional Investors / Research Analysts 08 Feb Intimation of Postal Ballot and Cut-off date 04 Feb Cancer Task Force Recommends Guidelines for Cancer Care- Press Release   January 2019 29 Jan Meetings conducted with Institutional Investors/Research Analysts 25 Jan Press Release for the quarter ended December 31, 2018 24 Jan Outcome of Board meeting held on January 24, 2019 24 Jan Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2018 09 Jan Intimation of Board Meeting

January to July 2020  January to December 2019  January to December 2018  January to December 2017  January to December 2016  December 2015

Biocon Businesses Recommended sites Biocon on     Home About Us Investor Relations Media Relations Careers Site Map Contact Us Our Growth Accelerators Fact Sheet Branded Formulations Biopharmaceuticals Research Services Active Discovery Program ABLE Karnataka Vision Group on BT Syngene International Biocon Academy                   Report adverse event/side effects and product complaints               * Disclaimer            © 2018, Biocon. All Rights Reserved